Developer docs
API playgroundTry for free, no card

Search company profiles

InnoSer

Full company profile

uuid0003gbf

Namestring
InnoSer
Legal namestring
InnoSer Laboratories BV
Company typeenum
Private
Founded yearint
2016
Descriptiontext

InnoSer is a privately held European preclinical Contract Research Organization (CRO) operating from AAALAC-accredited facilities in Leiden, Netherlands (since 2016) and Diepenbeek, Belgium (since 2020). Founded in 2011 as InnoSer Laboratories BV, the company provides fee-for-service translational preclinical research for pharmaceutical and biotechnology clients, with a customer base of 200+ that includes large pharma (Roche, AstraZeneca, Daiichi-Sankyo, Bayer, Novo Nordisk) and biotech firms ranging from mid-market (Bial, Carthera, Agomab) to early-stage startups (Montis, Upyther, Illimis, Regel, NTrans).

The core platform combines proprietary genetically modified mouse models, an integrated behavioral testing battery (PhenoTyper home-cages with AHCODA analytics, CatWalk XT gait analysis, Morris Water Maze, rotarod, grip strength), histopathology/IHC, MSD-based biomarker bioanalysis (Aβ42/40, pTau181, total Tau, NfL in plasma/CSF), longitudinal ultrasound imaging, and 3R-compliant vivarium management. Notable proprietary assets include the Tau[P301S] and APP[V717I]xTau[P301S] transgenic Alzheimer's models, an ADPKD P10/P18/P40 tamoxifen-inducible platform with FDA/EMA-aligned total kidney volume biomarker readouts, and the SonoCloud ultrasound-mediated BBB drug-delivery service. The InnoSer Acceleration Program (ISAP) extends the offering to startups and academic spinoffs with tiered milestone-based support and vivarium rental.

InnoSer's go-to-market combines direct enterprise sales (Business Development Managers and Product Managers), conference-led demand generation across therapeutic venues (AD/PD, CKD Drug Development Summit, Global NASH Congress), and content marketing via scientific newsletters and downloadable technical leaflets. Pricing is quote-based with an explicit 'transparent upfront costs, no hidden fees' value proposition. Revenue model is professional services (project-based CRO contracts), with no public revenue disclosure and only one disclosed funding round (~€1M from Limburgse Reconversie Maatschappij in September 2016). Core scientific alliances include Sylics (Synaptologics BV), VU University Amsterdam's CNCR, Novo Nordisk, MAT BioTech, and TU Eindhoven.

Short descriptiontext

InnoSer is a European preclinical CRO operating AAALAC-accredited facilities in the Netherlands and Belgium, providing fee-for-service translational research — including proprietary genetically modified mouse models, behavioral testing, biomarker bioanalysis, and histopathology — to 200+ pharmaceutical and biotechnology clients across neurology, oncology, nephrology, immunology, cardiovascular, and metabolic disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersDiepenbeek, Belgium
HQ citystring
Diepenbeek
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical CRO services, contract research organization, animal model research, drug discovery services, translational research
Industry3 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
NAICS code1 code
  • Other Scientific and Technical Consulting Services54169
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Contract Research
Social media profiles3 records
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model2 records
1Preclinical CRO Contract Research Services
TypeProfessional Services
Description

Fee-for-service preclinical contract research spanning in vivo pharmacology, in vitro assays, behavioral testing, histopathology, biomarker bioanalysis, and colony management; project-based engagement with dedicated study directors and customized study design per client program.

innoserlaboratories.com
2InnoSer Acceleration Program (ISAP) and Vivarium Rental
TypeProfessional Services
Description

Customized compound development program for startups and academic spinoffs offering flexible support tiers, access to fully equipped in vitro/in vivo rental spaces, and tailored milestone-based research support.

innoserlaboratories.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Quote-based, project-tier CRO service pricing
ModelOther
Notes

Pricing determined per study based on scope, models, readouts, and duration; transparent upfront costs emphasized.

innoserlaboratories.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

InnoSer is a European preclinical Contract Research Organization (CRO) providing fee-for-service drug discovery and preclinical development offerings to biotech and pharmaceutical companies. Its core services span in vivo pharmacology using proprietary and validated genetically modified mouse models, rodent behavioral testing, histopathology and biomarker bioanalysis, colony management, and vivarium/facility rental, organized across therapeutic areas including neurology, oncology, immunology, nephrology, metabolic, and cardiovascular disease.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

InnoSer is a European preclinical contract research organization (CRO) offering a unified services platform for drug discovery and translational research, structured around core service modules (In Vivo Models, Rodent Behavioral Testing, Pathology, Colony Management, and Facility Management) and the InnoSer Acceleration Program (ISAP) compound development program. The platform is organized by research area expertise — including Neurology, Oncology, Immunology, Nephrology, Metabolic, and Cardiovascular services — and delivered through an extensive portfolio of disease-specific mouse models such as the Tau[P301S], APP[V717I] x Tau[P301S], Tau Seeding Mouse Models, P40 ADPKD Mouse Model, and broader Alzheimer's Disease and Rare Disease Mouse Model collections. Together, these products and modules support clients from target validation through IND-enabling preclinical development.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeStrategic or Co-development Partner
Description

InnoSer maintains close collaboration with TU Eindhoven as a consortium partner; product manager Tim Rodenburg regularly visits TU Eindhoven's research groups (e.g., the Luttge group) for collaborative work.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sylics is a key scientific collaboration partner on neurodegenerative disease behavioral phenotyping. Together they developed PhenoTyper home-cage AHCODA analytical methods for discriminating neurodegeneration from healthy aging (presented at AD/PD 2023). Sylics is also a collaboration partner on NAFLD/cognitive deficit research presented at the 6th Global NASH Congress 2023 with Novo Nordisk. Several shared scientific staff (Bastijn Koopmans, Maarten Loos, Joshua Obermayer) contribute to both organizations.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research collaboration on neurodegenerative disease behavioral phenotyping, co-developing home-cage behavior analysis methods with Sylics. Multiple CNCR faculty (Sabine Spijker, Ronald E. van Kesteren, Matthijs Verhage, August B. Smit) co-authored the AD/PD 2023 poster on discriminating neurodegeneration from healthy aging.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-development partner on a pilot study investigating western-style diet-induced cognitive deficits in C57BL/6J mice (presented at 6th Global NASH Congress 2023, London). The collaboration established a translatable mouse model platform for testing therapeutics targeting diet-induced cognitive impairment in metabolic disorders.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Labcorp (Covance)
TypeBroad incumbent
Description

Global CRO with extensive preclinical research services including in vivo pharmacology, safety assessment, and biomarker capabilities. Competes with InnoSer for pharma preclinical outsourcing budgets via its larger scale and integrated early-to-clinical development offerings.

TypeBroad incumbent
Description

China/UK/US-headquartered CRO with preclinical in vivo, DMPK, safety, and integrated discovery services. Overlaps with InnoSer in preclinical CRO services but offers much broader, integrated drug discovery-to-development scope.

TypeEmerging player
Description

Dutch behavioral phenotyping specialist that co-developed PhenoTyper/AHCODA with InnoSer; provides automated home-cage behavior analytics. Adjacent rather than directly competing, but operates in overlapping neurodegenerative disease phenotyping workflows with shared scientific staff.

TypeDirect peer
Description

Mid-sized CRO specializing in preclinical and clinical research across neuroscience, metabolic disease, and other therapeutic areas. Comparable in therapeutic focus (notably neurology and metabolic) and ability to serve mid-market biotech and large pharma preclinical needs.

TypeBroad incumbent
Description

Global preclinical and clinical CRO with extensive rodent model, in vivo pharmacology, and bioanalytical capabilities serving pharma and biotech. Comparable in service scope but competes from a much larger, Asia-rooted platform.

TypeBroad incumbent
Description

Global preclinical CRO with extensive rodent model, in vivo pharmacology, and safety assessment capabilities across oncology, neurology, and metabolic disease. Overlaps with InnoSer's full preclinical CRO platform but at vastly larger scale and broader geographic footprint.

TypeBroad incumbent
Description

European life sciences testing and CRO conglomerate offering preclinical, bioanalytical, and biomarker services. Adjacent competitor in bioanalytical/biomarker work and broader preclinical testing, with substantially greater scale and global footprint than InnoSer.

TypeDirect peer
Description

Preclinical CRO with deep oncology and immuno-oncology model portfolios (syngeneic, CDX, PDX, humanized models) plus translational biomarker capabilities. Directly comparable to InnoSer's oncology CRO services and biomarker offerings.

TypeBroad incumbent
Description

European drug discovery and preclinical CRO with multi-therapeutic area coverage, proprietary platforms, and partnerships with major pharma. Comparable in therapeutic breadth and European positioning to InnoSer, though operating at much larger scale and integrated discovery-to-clinical scope.

TypeDirect peer
Description

US-based preclinical CRO specializing in behavioral phenotyping and neurodegenerative disease models using transgenic mice and AI-driven analytics (e.g., NeuroCube). Closely comparable to InnoSer's neurology/CNS preclinical services and automated behavior platforms like PhenoTyper/AHCODA.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

InnoSer

Preclinical Contract Researchinnoserlaboratories.com

InnoSer is a European preclinical CRO operating AAALAC-accredited facilities in the Netherlands and Belgium, providing fee-for-service translational research — including proprietary genetically modified mouse models, behavioral testing, biomarker bioanalysis, and histopathology — to 200+ pharmaceutical and biotechnology clients across neurology, oncology, nephrology, immunology, cardiovascular, and metabolic disease.

What InnoSer does

InnoSer is a privately held European preclinical Contract Research Organization (CRO) operating from AAALAC-accredited facilities in Leiden, Netherlands (since 2016) and Diepenbeek, Belgium (since 2020). Founded in 2011 as InnoSer Laboratories BV, the company provides fee-for-service translational preclinical research for pharmaceutical and biotechnology clients, with a customer base of 200+ that includes large pharma (Roche, AstraZeneca, Daiichi-Sankyo, Bayer, Novo Nordisk) and biotech firms ranging from mid-market (Bial, Carthera, Agomab) to early-stage startups (Montis, Upyther, Illimis, Regel, NTrans).

The core platform combines proprietary genetically modified mouse models, an integrated behavioral testing battery (PhenoTyper home-cages with AHCODA analytics, CatWalk XT gait analysis, Morris Water Maze, rotarod, grip strength), histopathology/IHC, MSD-based biomarker bioanalysis (Aβ42/40, pTau181, total Tau, NfL in plasma/CSF), longitudinal ultrasound imaging, and 3R-compliant vivarium management. Notable proprietary assets include the Tau[P301S] and APP[V717I]xTau[P301S] transgenic Alzheimer's models, an ADPKD P10/P18/P40 tamoxifen-inducible platform with FDA/EMA-aligned total kidney volume biomarker readouts, and the SonoCloud ultrasound-mediated BBB drug-delivery service. The InnoSer Acceleration Program (ISAP) extends the offering to startups and academic spinoffs with tiered milestone-based support and vivarium rental.

InnoSer's go-to-market combines direct enterprise sales (Business Development Managers and Product Managers), conference-led demand generation across therapeutic venues (AD/PD, CKD Drug Development Summit, Global NASH Congress), and content marketing via scientific newsletters and downloadable technical leaflets. Pricing is quote-based with an explicit 'transparent upfront costs, no hidden fees' value proposition. Revenue model is professional services (project-based CRO contracts), with no public revenue disclosure and only one disclosed funding round (~€1M from Limburgse Reconversie Maatschappij in September 2016). Core scientific alliances include Sylics (Synaptologics BV), VU University Amsterdam's CNCR, Novo Nordisk, MAT BioTech, and TU Eindhoven.

InnoSer firmographics

Firmographics
Name
InnoSer
Legal name
InnoSer Laboratories BV
Website
https://innoserlaboratories.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
InnoSer is a European preclinical CRO operating AAALAC-accredited facilities in the Netherlands and Belgium, providing fee-for-service translational research — including proprietary genetically modified mouse models, behavioral testing, biomarker bioanalysis, and histopathology — to 200+ pharmaceutical and biotechnology clients across neurology, oncology, nephrology, immunology, cardiovascular, and metabolic disease.
Ownership category
akta.pro rank

InnoSer industry classification

Industry
Product category
Preclinical Contract Research
NAICS
Other Scientific and Technical Consulting Services (54169)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)

Keywords

  • Preclinical CRO services
  • Contract research organization
  • Animal model research
  • Drug discovery services
  • Translational research

Where InnoSer is headquartered

Location

Headquarters

HQ city
Diepenbeek
HQ country
Belgium
HQ region
Europe

Offices2 records

Markets served

InnoSer business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Preclinical CRO Contract Research Services: Fee-for-service preclinical contract research spanning in vivo pharmacology, in vitro assays, behavioral testing, histopathology, biomarker bioanalysis, and colony management; project-based engagement with dedicated study directors and customized study design per client program.
  2. InnoSer Acceleration Program (ISAP) and Vivarium Rental: Customized compound development program for startups and academic spinoffs offering flexible support tiers, access to fully equipped in vitro/in vivo rental spaces, and tailored milestone-based research support.

Pricing tiers

ModelBillingPrice
Other—Quote-based, project-tier CRO service pricing

Go-to-market motion4 records

Distribution channels3 records

Marketing channels7 records

InnoSer product offering

Product offering

Core offering

InnoSer is a European preclinical Contract Research Organization (CRO) providing fee-for-service drug discovery and preclinical development offerings to biotech and pharmaceutical companies. Its core services span in vivo pharmacology using proprietary and validated genetically modified mouse models, rodent behavioral testing, histopathology and biomarker bioanalysis, colony management, and vivarium/facility rental, organized across therapeutic areas including neurology, oncology, immunology, nephrology, metabolic, and cardiovascular disease.

Product overview

InnoSer is a European preclinical contract research organization (CRO) offering a unified services platform for drug discovery and translational research, structured around core service modules (In Vivo Models, Rodent Behavioral Testing, Pathology, Colony Management, and Facility Management) and the InnoSer Acceleration Program (ISAP) compound development program. The platform is organized by research area expertise — including Neurology, Oncology, Immunology, Nephrology, Metabolic, and Cardiovascular services — and delivered through an extensive portfolio of disease-specific mouse models such as the Tau[P301S], APP[V717I] x Tau[P301S], Tau Seeding Mouse Models, P40 ADPKD Mouse Model, and broader Alzheimer's Disease and Rare Disease Mouse Model collections. Together, these products and modules support clients from target validation through IND-enabling preclinical development.

Differentiator

Problem solved

Functional benefit

Companies that use InnoSer

Customer profile

Named customers14 records

Segments7 records

Ideal customer profiles4 records

InnoSer technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature10 records

InnoSer partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • TU EindhovenminorStrategic or Co-development PartnerInnoSer maintains close collaboration with TU Eindhoven as a consortium partner; product manager Tim Rodenburg regularly visits TU Eindhoven's research groups (e.g., the Luttge group) for collaborative work.
  • Sylics (Synaptologics BV)coreStrategic or Co-development PartnerSylics is a key scientific collaboration partner on neurodegenerative disease behavioral phenotyping. Together they developed PhenoTyper home-cage AHCODA analytical methods for discriminating neurodegeneration from healthy aging (presented at AD/PD 2023). Sylics is also a collaboration partner on NAFLD/cognitive deficit research presented at the 6th Global NASH Congress 2023 with Novo Nordisk. Several shared scientific staff (Bastijn Koopmans, Maarten Loos, Joshua Obermayer) contribute to both organizations.
  • VU University Amsterdam - Center for Neurogenomics and Cognitive Research (CNCR)coreStrategic or Co-development PartnerAcademic research collaboration on neurodegenerative disease behavioral phenotyping, co-developing home-cage behavior analysis methods with Sylics. Multiple CNCR faculty (Sabine Spijker, Ronald E. van Kesteren, Matthijs Verhage, August B. Smit) co-authored the AD/PD 2023 poster on discriminating neurodegeneration from healthy aging.
  • Novo Nordisk A/ScoreStrategic or Co-development PartnerCo-development partner on a pilot study investigating western-style diet-induced cognitive deficits in C57BL/6J mice (presented at 6th Global NASH Congress 2023, London). The collaboration established a translatable mouse model platform for testing therapeutics targeting diet-induced cognitive impairment in metabolic disorders.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

InnoSer competitors and assessment

Company assessment

Broad incumbents

  • Labcorp (Covance): Global CRO with extensive preclinical research services including in vivo pharmacology, safety assessment, and biomarker capabilities. Competes with InnoSer for pharma preclinical outsourcing budgets via its larger scale and integrated early-to-clinical development offerings.
  • Pharmaron: China/UK/US-headquartered CRO with preclinical in vivo, DMPK, safety, and integrated discovery services. Overlaps with InnoSer in preclinical CRO services but offers much broader, integrated drug discovery-to-development scope.
  • Wuxi AppTec: Global preclinical and clinical CRO with extensive rodent model, in vivo pharmacology, and bioanalytical capabilities serving pharma and biotech. Comparable in service scope but competes from a much larger, Asia-rooted platform.
  • Charles River Laboratories: Global preclinical CRO with extensive rodent model, in vivo pharmacology, and safety assessment capabilities across oncology, neurology, and metabolic disease. Overlaps with InnoSer's full preclinical CRO platform but at vastly larger scale and broader geographic footprint.
  • Eurofins Scientific: European life sciences testing and CRO conglomerate offering preclinical, bioanalytical, and biomarker services. Adjacent competitor in bioanalytical/biomarker work and broader preclinical testing, with substantially greater scale and global footprint than InnoSer.
  • Evotec: European drug discovery and preclinical CRO with multi-therapeutic area coverage, proprietary platforms, and partnerships with major pharma. Comparable in therapeutic breadth and European positioning to InnoSer, though operating at much larger scale and integrated discovery-to-clinical scope.

Emerging players

  • Sylics (Synaptologics BV): Dutch behavioral phenotyping specialist that co-developed PhenoTyper/AHCODA with InnoSer; provides automated home-cage behavior analytics. Adjacent rather than directly competing, but operates in overlapping neurodegenerative disease phenotyping workflows with shared scientific staff.

Direct peers

  • QPS Holdings: Mid-sized CRO specializing in preclinical and clinical research across neuroscience, metabolic disease, and other therapeutic areas. Comparable in therapeutic focus (notably neurology and metabolic) and ability to serve mid-market biotech and large pharma preclinical needs.
  • Crown Bioscience (JSR Life Sciences): Preclinical CRO with deep oncology and immuno-oncology model portfolios (syngeneic, CDX, PDX, humanized models) plus translational biomarker capabilities. Directly comparable to InnoSer's oncology CRO services and biomarker offerings.
  • PsychoGenics: US-based preclinical CRO specializing in behavioral phenotyping and neurodegenerative disease models using transgenic mice and AI-driven analytics (e.g., NeuroCube). Closely comparable to InnoSer's neurology/CNS preclinical services and automated behavior platforms like PhenoTyper/AHCODA.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

InnoSer social profiles

Digital presence

InnoSer compliance and trust

Trust signal

Compliance2 records

InnoSer financial estimates

Financial estimate

Revenue estimate

Valuation estimate

InnoSer leadership team

Management profile

Number of profiles

Profiles11 records

InnoSer funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

InnoSer M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InnoSer

What does InnoSer do?

InnoSer is a European preclinical Contract Research Organization (CRO) providing fee-for-service drug discovery and preclinical development offerings to biotech and pharmaceutical companies. Its core services span in vivo pharmacology using proprietary and validated genetically modified mouse models, rodent behavioral testing, histopathology and biomarker bioanalysis, colony management, and vivarium/facility rental, organized across therapeutic areas including neurology, oncology, immunology, nephrology, metabolic, and cardiovascular disease.

Is InnoSer a public or private company?

InnoSer is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was InnoSer founded?

InnoSer was founded in 2016. It employs 51 to 100 people.

Where is InnoSer based?

InnoSer is headquartered in Diepenbeek, Belgium, in the Europe region.

How does InnoSer make money?

Two revenue lines are on record. Preclinical CRO Contract Research Services are the primary driver. The others are innoSer Acceleration Program (ISAP) and Vivarium Rental.

Who are InnoSer's main competitors?

Broad incumbents on record are Labcorp (Covance), Pharmaron, Wuxi AppTec, Charles River Laboratories, Eurofins Scientific and Evotec. Sylics (Synaptologics BV) is listed as an emerging player. Direct peers are QPS Holdings, Crown Bioscience (JSR Life Sciences) and PsychoGenics.

Does InnoSer have an API?

No public API is recorded for InnoSer.

What industry is InnoSer in?

InnoSer's product category is Preclinical Contract Research. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAC, Toxicology & Safety Assessment CROs (GLP). Its NAICS code is 54169 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals